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PRECIS 
In this large population-based cohort study, compared to never smokers, current smokers at 
diagnosis had a statistically significant raised death rate from cancer. The effect of current smoking 
was not modified by age, or receipt of tumor-directed surgery, radiotherapy or chemotherapy, but 
was slightly stronger in males than females. 
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ABSTRACT 
Background: Five-year survival for rectal cancer remains <60%. The identification of potentially 
modifiable prognostic factors would be of considerable public health importance. A few studies 
suggest associations between smoking and survival in rectal cancer, but the evidence is inconsistent 
and most studies are relatively small. In a large, population-based, cohort study we investigated: 
whether smoking at diagnosis is an independent prognostic factor for cancer-specific survival in 
rectal cancer; and whether the association varies by sex, age and treatment.   
Methods: Rectal cancers (ICD10 C19-20) diagnosed 1994-2012 were abstracted from the National 
Cancer Registry Ireland, and classified by smoking status at diagnosis. Follow-up was for 5 years or 
until 31st December 2012. Multivariable Cox proportional hazards models were used to compare 
cancer-specific death rates in current, ex- and never smokers. Subgroup analyses by age at diagnosis, 
sex, and treatment were conducted.  
Results: 10,794 rectal cancers were diagnosed. At diagnosis, 25% were current smokers, 24% ex-
smokers and 51% never smokers. Compared to never smokers, current smokers had a significantly 
raised death rate from cancer (multivariable HR=1.15, 95%CI 1.06-1.24), but ex-smokers did not 
(HR=1.02, 95%CI 0.94-1.11).  The association was slightly stronger in males (current vs never 
HR=1.13, 95%CI 1.02-1.24) than females (HR=1.05, 95%CI 0.90-1.23), but the test for interaction was 
not significant (p=0.75). The effect of smoking was not modified by age, or receipt of tumor-directed 
surgery, radiotherapy or chemotherapy.  
Conclusions: Rectal cancer patients who smoke at diagnosis have a statistically significant increased 
cancer death rate. Elucidation of the underlying mechanisms is urgently required.  
4 
 
INTRODUCTION 
Although rectal cancer outcomes have improved over time, average 5-year relative survival for 
patients diagnosed 2000-2007 in Europe was still only 56%.1 In addition, considerable variation in 
outcomes is evident. For example, within Europe 5-year relative survival ranges from 38% to 63%.1  
Moreover, there is variation within as well as between countries, with poorer outcomes observed 
among older, more socio-economically deprived, and rural patients.2-4 The identification of 
potentially modifiable prognostic factors would be of considerable public health importance.  
In this regard, there is growing interest in the influence of lifestyle behaviours on cancer survival 
(see, for example,5).  The US Surgeon General recently judged that there is sufficient evidence to 
consider smoking a causal agent for poorer cancer outcomes.6 Pre-diagnostic smoking is a causal 
factor for developing colorectal cancer and, in some studies, the relationship is stronger and more 
consistent with rectal than colon cancer.7,8  Less is known about whether smoking influences survival 
among those with rectal cancer. 
A recent systematic review identified 15 studies of smoking and survival in colorectal cancer9 and 
estimated a combined all-cause hazard ratio for current smokers of 1.26 (95%CI 1.15-1.37). 
However, only seven studies have reported separately on rectal cancer10-16 and only two of these 
found significant associations between current smoking and rectal cancer mortality.10,13 Two studies 
suggested the effect of smoking on mortality/survival was stronger in older patients11,15 and three 
that it was limited to, or stronger in, men,13,15,16 but most of these analyses included all colorectal 
cancers.  The study sizes were modest: the number of rectal cancer cases (or deaths) ranged from 
121 to 1514. Moreover, only one study identified subjects via a population-based registry, but this 
focussed primarily on younger patients.11 Finally, despite evidence that smoking can adversely affect 
post-resection outcomes (see, for example, 9,17,18) and perhaps also chemoradiation response19 no 
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studies appear to have considered whether treatment modifies associations between smoking and 
survival.   
We conducted a large, population-based, cohort study to investigate whether smoking status at 
diagnosis is an independent prognostic factor for cancer-specific survival among incident rectal 
cancers. Our secondary aims were to determine whether this association varied by sex, age or 
treatment. 
METHODS 
Data 
Data were derived from the National Cancer Registry Ireland, which records all incident cancers in 
Ireland (www.ncri.ie). Registration completeness exceeds 97%.20 Trained tumor registration officers 
collect patient, tumor and treatment details for each registration following internationally-accepted 
registration and coding conventions. Patients’ smoking status at diagnosis, as recorded in their 
hospital records, is also collected.   
Rectal cancers diagnosed 1994-2012 (ICD10 C19-20, n=13,857) were abstracted from the Registry. 
Cases were excluded if they were identified from death certificates only (n=140), had another cancer 
(other than a non-melanoma skin cancer) diagnosed since 01/01/1994 (n=2,014), or had tumor 
morphology other than adenocarcinoma (n=909).  
Death ascertainment, achieved by linking registrations to death notifications, was complete to 
31/12/2012. Rectal cancer-specific deaths were defined as those for which the underlying cause of 
death was coded as cancer: at the same diagnosis site; of the same body system; of another 
specified site; or of unknown site.21 
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Individuals were categorised by whether they had had (i) tumor-directed surgery, (ii) radiotherapy, 
or (iii) chemotherapy within a year of diagnosis. Summary stage at diagnosis was defined using the 
UICC classification. Address at diagnosis was used to assign each patient to a deprivation category, 
ranging from least (1) to most (5) deprived, based on a score derived from 2002 census variables.22 
Other socio-demographic variables were derived from Registry records. 
Smoking status at diagnosis was classified as: never smoked; ex-smoker (smoked at least once every 
month in the past but not in the previous year); and current smoker (smoked at least once every 
month in the previous year).  Smoking at diagnosis was missing for 23% (n=2,512) of cases, and 
missingness varied by patient-related, tumor-related and treatment variables (Supplemental Table 
1). Tumor stage and grade, both important prognostic factors,23,24 were incomplete or missing for 9% 
(n=987) and 13% (n=1,430) of cases respectively.  Missing data items in these three fields were 
populated using multiple imputation by chained equations.25 Fifty datasets were generated, in which 
missing values for smoking status, grade and stage were imputed using multinomial logistic 
regression (Supplemental Table 2). Multiple imputation produces less biased estimates than 
complete case analysis under a range of missing data scenarios and, under other scenarios, is more 
efficient than complete case analysis.26   
Statistical analysis 
The primary analyses were based on the dataset containing the imputed data. The initial analysis 
included all cases. Analyses was repeated for subgroups defined by sex, age-group at diagnosis, 
treatment, diagnostic period and stage. Survival time was computed from the date of diagnosis to 
date of death, 5-years of follow-up, or the censoring date (31/12/2012), whichever occurred first. 
Non-cancer deaths were censored when computing cancer-specific survival.  Characteristics of cases 
classified as never, ex- and current smokers at diagnosis were compared using chi-square tests.  
Unadjusted and multivariable hazard ratios for cancer-specific death within 5-years by smoking 
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status were computed using Cox proportional hazard regression. Hazard ratio estimates from the 50 
imputed datasets were combined to give a single estimate and standard error adjusted for inter- and 
intra-imputation variance following Rubin’s rules.27 A backwards stepwise approach was used to 
identify patient-related and clinical confounders, with variables retained at a Wald test p-value<0.05. 
The hazards for age-group (categorised as <55, 55-64, 65-74, 75+), stage and treatment were not 
proportional, so these variables were fitted as strata.  The same approach was used to build the 
stratified models. In these analyses age-group was categorised as <65/≥65; treatment as cancer-
directed surgery yes/no, radiotherapy yes/no and chemotherapy yes/no; stage as loco-regional 
(stage I/II/III)/metastatic (IV); and period as 1994-2006/2007-2012.  Interactions between smoking 
and these variables were tested by fitting cross-product terms. To aid interpretation, curves were 
generated of cumulative incidence of cancer-specific deaths and deaths due to other causes, by 
smoking status.  Throughout a two-sided p value of ≤0.05 was considered statistically significant. 
Sensitivity analyses were conducted in the “complete case” dataset. Unadjusted and adjusted hazard 
ratios by smoking status were computed restricting consideration to patients without missing data 
for smoking status, stage or grade (n=6,829).  A further sensitivity analysis was undertaken using 
competing risk regression in both the imputed and complete case datasets. 
RESULTS 
Primary analyses: multiple imputed dataset 
Ten thousand seven hundred and ninety-four rectal cancers were included.  After imputation, 51% 
were classified as never smokers at diagnosis, 24% as ex-smokers and 25% as current smokers (Table 
1). Two-thirds were male; 40% were under 65 at diagnosis; almost four-fifths (78%) had tumor-
directed surgery within a year of diagnosis, 38% had radiotherapy and 46% had chemotherapy. The 
distributions of all of the socio-demographic and clinical variables varied significantly by smoking 
status (Table 1). 
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There were 4,491 cancer-specific deaths during 5-years post-diagnosis. The cumulative incidence of 
cancer-specific death was highest in current smokers and lowest in never smokers (Supplemental 
figure 1(a)). For non-cancer deaths, the cumulative incidence was higher in current and ex-smokers 
than never smokers (Supplemental figure 1(b)). 
Among all patients, in the univariate analysis, compared to never smokers, ex-smokers had a 
modest, but non-significant, increased hazard while current smokers had a significantly increased 
hazard (Table 2). After adjustment for significant prognostic factors current smokers still had a 
significantly raised rate of cancer death (multivariable HR=1.15, 95%CI 1.06-1.24). The hazard in ex-
smokers was close to unity (HR=1.02, 95%CI 0.93-1.11).  
Effect modification analyses are shown in Supplemental Table 3. A significantly increased rate of 
cancer death among current, compared to never, smokers was evident for males (multivariable 
HR=1.13, 95%CI 1.02-1.24) but not females (HR=1.05, 95%CI 0.90-1.23). The test for interaction was 
not statistically significant (p=0.75).  Similarly, there was a significant association between current 
smoking and cancer death in loco-regional disease (multivariable HR=1.18, 95%CI 1.06-1.32), but not 
metastatic disease, but the test for interaction was not significant (p(interaction)=0.12). There was 
no evidence of any interactions between smoking and age at diagnosis (p(interaction)=0.76), 
treatment receipt (tumor-directed surgery p(interaction)=0.93; radiotherapy p(interaction)=0.69); 
chemotherapy p(interaction)=0.64)) or period of diagnosis (p(interaction)=0.78)  
Sensitivity analyses: complete case dataset 
Supplemental Table 4 shows the characteristics of the 6,829 patients in the complete case analysis.  
In univariate analyses current smokers had a 23% higher rate of cancer-specific death than never 
smokers, but this was attenuated after adjustment (multivariable HR=1.08, 95%CI 0.99-1.18; 
Supplemental Table 5). 
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Sensitivity analyses: competing risks regression 
In the imputed dataset, the multivariable hazard ratios for rectal cancer deaths, treating other 
causes as competing risks, were 1.15 (95%CI 1.06-1.25) and 1.03 (95%CI 0.95-1.13) for current and 
ex-smokers respectively. The results for the complete case dataset were similar (not shown). 
DISCUSSION 
In this population-based cohort study – by far the largest study to date on smoking and rectal cancer 
survival – we found a significantly increased rate of cancer-specific death in the 5-years post-
diagnosis in current versus never smokers. There was a suggestion that the association was limited 
to, or stronger in, men, but it did not differ between older and younger patients or by receipt of 
surgery, radiotherapy or chemotherapy. The detrimental effect of smoking was limited to current 
smokers; in the main, ex-smokers did not have a higher cancer-specific death rate than never 
smokers.  
Although significant, the magnitude of the association between smoking at the time of diagnosis and 
survival was relatively modest and the effect size was smaller than reported in some other studies 
(although risk estimates were not always statistically significant in these other studies).10,12,13 Our 
study was population-based so there was no possibility of selection, or participation, of patients with 
particular patterns of smoking exposure.  Unlike other studies we adjusted for deprivation, which is 
a marker of socio-economic status. In many populations, including Ireland, smoking is more common 
in lower socio-economic groups, and/or more deprived areas.28 In addition, deprivation, or lower 
socio-economic status, has been negatively associated with rectal cancer survival2 so this adjustment 
would be expected to attenuate the observed risk estimate for smoking. 
The slightly stronger association with current smoking in males than females is broadly consistent 
with findings elsewhere; two colorectal cancer survival studies reported that the association was 
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limited to males15,16 and a rectal cancer study found a significant association between current 
smoking and mortality only in males.13 Almost twice as many rectal cancers were diagnosed in males 
than females in Ireland during 1994-2012 and, among cases (as in the general population29) current 
smoking prevalence was higher in males (28% vs 19%).  Thus our study (in common with others) will 
have had lower power to detect modest associations in females than males. Studies suggest that 
males may be more likely to deny smoking than females,30,31 so the true difference in the hazard by 
sex may be greater than observed. In terms of explanations, males start smoking earlier and smoke 
more cigarettes on average32 likely resulting in higher cumulative exposure by diagnosis; they may be 
more likely to continue smoking post-diagnosis than females;33  and they may be more often 
exposed to other lifestyle factors (e.g. obesity, unhealthy diet, high alcohol intake, lower physical 
activity) which are associated both with smoking and poorer survival/higher mortality from 
colorectal cancer.14,34-36  
The evidence that smoking adversely affects post-surgical outcomes in colorectal cancer (including 
complications,18  wound healing17 and 30-day mortality9) suggests that smoking might be particularly 
detrimental for survival among surgical patients. In fact we found no evidence for this: hazard ratios 
for current versus never smokers were almost identical in the surgery and non-surgery groups. 
However, there are challenges in interpreting analyses comparing surgery and non-surgery groups, 
because patients who die soon after diagnosis have no possibility of undergoing surgery.  Post hoc 
we undertook a landmark analysis in the multiple imputed dataset, restricting consideration to 
patients alive six months post-diagnosis; the hazard ratios for current versus never smokers were the 
same among surgical (multivariable HR=1.10, 0.97-1.24) and non-surgical patients (multivariable 
HR=1.10, 0.91-1.33).  
Mechanisms  
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The mechanism(s) by which smoking might affect rectal cancer survival are not understood. Smokers 
are more likely to have comorbid conditions; these might adversely impact survival among current 
smokers either directly (e.g. by increasing risk of complications post-surgery) or indirectly (e.g by 
influencing treatment receipt). Information is lacking on whether smoking is associated with 
recurrence, distant metastases, or second primaries in rectal cancer. In terms of genetic and 
epigenetic effects, smoking is related to increased DNA damage and reduced repair capacity37 and 
polymorphisms in DNA repair genes have been associated with colorectal cancer survival.38  
Similarly, smoking can induce aberrant DNA methylation39 and differential methylation has been 
associated with rectal cancer recurrence and survival.40-42 However, whether smoking, DNA repair or 
methylation, and rectal cancer survival are inter-related remains unknown. 
Smoking also impacts on inflammatory response43 and immune competence.44  An inflammation-
related pathway has been implicated in rectal cancer aetiology;45 systemic inflammatory response 
predicts outcome in rectal patients undergoing neo-adjuvant chemoradiation;46 and pre-surgical 
inflammatory score may be a prognostic factor following colorectal resection.47 However, inter-
relationships between inflammatory markers and smoking in predicting rectal cancer survival do not 
appear to have been investigated. 
Strengths and limitations   
The size and population-basis are major strengths of the study. Because information was derived 
from routine medical records, smoking status was unknown for 23% of patients.  Using multiple 
imputation to populate missing data generates effect estimates likely to be less biased than those 
resulting from other approaches for dealing with missing data.  Morrison et al.10 suggested reverse 
causality may affect associations between smoking and rectal cancer mortality, because smokers 
may quit shortly before diagnosis due to symptoms. This could explain why prevalence of current 
smoking in rectal cancer patients (25%) was lower than in the general population in Ireland in 2003 
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(males, 30%; females, 27%).29 In addition, some current smokers may have been recorded in their 
medical records as never smokers; if so we will have under-estimated the true effect of smoking at 
diagnosis on cancer-specific mortality. However, the limited available data suggests high 
correspondence between self-reported smoking status and biochemical measures among newly 
diagnosed cancer patients.48 We lacked information on duration and intensity of tobacco exposure, 
whether smoking status changed after diagnosis, and on comorbidities, which are likely to be more 
common among smokers.49 The use of cancer-specific survival was intended to account for deaths 
due to smoking-related comorbidities. While a considerable proportion of death certificates may be 
inaccurate,50 there does not appear to be any published data on whether accuracy is differential by 
smoking status, or whether deaths from smoking-related conditions (such as COPD) in cancer 
patients tend to be misattributed to cancer. Since competing risks can be a concern in cause-specific 
survival analysis, it was reassuring that the results of the competing risk regression sensitivity 
analysis were consistent with those of the cause-specific analysis.  Moreover, while survival methods 
which are not dependent on accuracy of cause of death are available, these also have limitations.51 
Finally, any under-ascertainment of treatments could diminish true differences between the 
treatment strata. While the overall utilisation of radiotherapy appeared low, it was higher among 
patients with rectal, than rectosigmoid, tumors and increased over time to, in 2007-12, a level 
consistent with figures from the American College of Surgeons’ National Cancer Database.52 Similar 
observations apply to chemotherapy. Thus any misclassification is likely to be modest.  
Conclusions 
This large, population-based, study found that rectal cancer patients who smoke at diagnosis have a 
statistically significant increased rate of death from cancer. This effect may be limited to, or stronger 
in, men. Elucidation of the mechanisms underlying this association is urgently required.  Meanwhile, 
greater efforts to support smoking cessation in those at risk of, and diagnosed with, rectal cancer 
would be beneficial. 
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Table 1. Primary analysis1: demographic, tumor and treatment characteristics of patients with rectal cancer 
diagnosed 1994-2012: percentages of patients, overall and by smoking status at diagnosis, and p values from chi-
square tests2 
Characteristic  
Never 
smokers 
 
Ex- 
smokers 
 
Current 
smokers 
 
All  
patients 
Age-group at 
diagnosis 
<55 16.3  11.3  21.1  16.3 
55-64 22.5  23.4  26.3  23.6 
  65-74 29.7  33.8  30.8  31.0 
  75+ 31.5  31.5  21.8  29.1 
  p<0.01   
Sex male 55.8  75.1  73.0  64.7 
  female 44.2  24.9  27.0  35.3 
  p<0.01   
Marital status other3 41.2  36.6  45.2  41.1 
  married 58.8  63.4  54.8  58.9 
  p<0.01   
Deprivation  1 (least deprived) 22.2  22.9  17.5  21.2 
category 2 15.0  14.4  13.9  14.6 
  3 14.2  13.9  13.5  14.0 
  4 18.8  17.3  17.2  18.0 
  5 (most deprived) 29.8  31.6  37.8  32.2 
  p<0.01   
Cancer site rectosigmoid (C19) 22.3  21.6  18.4  21.2 
  rectum (C20) 77.7  78.4  81.6  78.8 
    p<0.01     
Stage at I 20.1  19.6  16.9  19.2 
diagnosis II 25.5  24.4  25.9  25.3 
  III 34.0  33.5  31.2  33.2 
  IV 20.4  22.6  26.0  22.3 
  p<0.01   
Grade at  well differentiated 8.3  7.2  7.7  7.9 
diagnosis moderately 
differentiated 
78.1  80.5  80.1  79.2 
  poor/undifferentiated 13.6  12.3  12.2  12.9 
  p<0.01   
Period of 1994-2000 32.1  27.5  37.1  32.3 
diagnosis 2001-2006 31.6  32.7  30.1  31.5 
 2007-2012 36.3  39.8  32.7  36.2 
  p<0.01   
Cancer-directed 
surgery 
no 19.8  21.2  25.5  21.6 
yes 80.2  78.8  74.5  78.4 
    p<0.01     
Radiotherapy no 63.7  62.7  59.6  62.5 
  yes 36.3  37.3  40.4  37.5 
  p<0.01   
Chemotherapy no 54.4  54.8  54.8  54.2 
 yes 45.6  45.2  45.2  45.8 
  p<0.36   
1 multiple imputed dataset, n=10,794; the percentages reflect the average over 50 imputed datasets 
2 tests of association between patient characteristics and smoking status; tests done on average number of patients over 50 imputed datasets 
3 single, widowed, separated, divorced or unknown status  
2 
 
Table 2.  Primary analysis1: Cox model for all rectal cancers diagnosed 1994-2012: percentages of cancer-specific 
deaths over 5 years2, univariate and multivariable hazard ratios (HR), with 95% confidence intervals (95%CI) and 
Wald p values3 
  Cancer-specific 
deaths 
Univariate analysis Multivariable analysis4 
Variable   % HR 95%CI p HR 95%CI p 
         
Smoking never smoker 39.8 1 - <0.01 1 - <0.01 
Status5 ex-smoker 40.5 1.05 [0.97,1.14] 
 
1.02 [0.93,1.11] 
 
 
current smoker 46.4 1.23 [1.14,1.33] 
 
1.15 [1.06,1.24] 
 
Age-group 
at 
<55 33.9 1 - <0.01 
   
diagnosis 55-64 35.4 1.07 [0.96,1.18] 
    
 
65-74 41.3 1.38 [1.25,1.52] 
    
 
75+ 51.2 2.13 [1.94,2.34] 
    
Sex male 42.8 1 - <0.01 1 - <0.01 
 
female 39.5 0.89 [0.83,0.94] 
 
0.89 [0.83,0.95] 
 
Marital other 46.5 1 - <0.01 1 - <0.01 
status married 38.2 0.70 [0.66,0.75] 
 
0.83 [0.78,0.89] 
 
Deprivation 1 (least deprived) 37.6 1 - <0.01 1 - <0.01 
category 2 41.6 1.13 [1.02,1.25] 
 
1.04 [0.94-1.15]  
 
3 40.6 1.12 [1.01,1.24] 
 
1.07 [0.97-1.19]  
 
4 42.9 1.18 [1.07,1.30] 
 
1.10 [1.00-1.22]  
 
5 (most deprived) 43.9 1.28 [1.18,1.39] 
 
1.18 [1.08-1.28]  
Period of 1994-1999 53.5 1 - <0.01 1 - <0.01 
diagnosis 2000-2006 47.2 0.82 [0.77,0.88] 
 
0.76 [0.71,0.81] 
 
 
2007-2012 26.2 0.57 [0.53,0.62] 
 
0.53 [0.49,0.57] 
 
Cancer site C19: rectosigmoid 42.2 1 - 0.48 
   
 
C20: rectum 41.4 0.97 [0.91,1.05] 
    
Grade well differentiated 41.0 1 - <0.01 1 - <0.01 
 
moderately 
differentiated 
39.1 1.02 [0.90,1.15] 
 
1.04 [0.92,1.17] 
 
 
poorly/undifferentiated 57.6 1.85 [1.62,2.12] 
 
1.62 [1.41,1.86] 
 
Stage at I 15.0 1 - <0.01 
   
diagnosis II 32.7 2.54 [2.22,2.91] 
    
 
III 37.9 3.14 [2.76,3.57] 
    
 
IV 80.1 12.62 [11.12,14.32] 
    
1 multiple imputed dataset, n=10,794, with 4,491 (41.6%) cancer-specific deaths in 5 years 
2 percentage that died from cancer, averaged over 50 imputed datasets 
3 from significance test of the relevant variable 
4 multivariable model, with stage and age-group fitted as stratification factors as hazards for these variables were not proportional 
5 at diagnosis
3 
 
 
